Diagnosis

Temporal arteritis

A chronic granulomatous inflammatory systemic vasculitis affecting small-sized, medium-sized, and large-sized arteries, primarily the superficial temporal arteries.

Also known as: Cranial arteritis, Giant cell arteritis, Horton’s arteritis

Etiology

Cause [t61][bty][pya]

Pathophysiology [t61]

  1. Activation of immune responses by presenting antigens --> T lymphocytes --> pro-inflammatory cytokines --> activation of macrophages and multinucleated giant cells:

    • Granulomatous vasculitis in medium- and large-sized arteries

  2. Localisation:

    • Vertebral arteries, subclavian arteries, temporal/ophthalmic/occipital/ciliary arteries

  3. Clinical manifestation:

    • Headache

    • Fever, malaise, depression, anorexia, and weight loss

    • Visual disturbances: scotoma

    • Jaw claudication, tongue pain

    • Musculoskeletal: Polymyalgia rheumatica (myalgia, stiffness)

    • Abnormal temporal artery biopsy

    • Upper extremity claudication, Raynaud phenomenon

    • CNS: Transient ischemic attacks or stroke

Complications [bty][pya]

Epidemiology

Incidence per 100.000 [f4t][sfc][bty][t61]

Epidemiology chart for Incidence

Symptoms & findings

Symptoms

Blindness, Blurred vision, Claudication, Diplopia, Dizziness, Fatigue, Fever, Hallucinations, Headache, Jaw claudication, Malaise, Myalgia, Night sweats, Scotoma, Stiffness, Vertigo, Weight loss

Clinical findings

Anemia, Elevated CRP, Elevated Sedimentation Rate

Anamneses

None listed.

Localized findings

Pain
Radiates
EyesRegio deltoidea (Shoulder)Regio cervicalis lateralisLumbarSacralHipRegio glutealisRegio femoralis
Onset
Subacute (hours)Gradual (days)
Severity
Mild (1-3)Moderate (4-7)

Approach

GCA Classification Criteria

3 or more of the following parameters:

Treatment

  1. Prednisolone 40 to 60 mg/day for 2 to 4 weeks [bty][pya]

    • If impending danger of blindness --> IV methylprednisolone 1 g/day for 3 days

  2. If clinical remission, decrease the dose to reach 20 mg/day and later 10 mg/day

  3. Aspirin (81 mg) --> prevention of visual loss and stroke

  4. Biologic agents: Tocilizumab (IL-6 inhibitor antagonist)

  5. Management of dietary sugar, salt, and caloric intake

Differential diagnoses

Endocarditis, Microscopic polyangiitis, Optic neuritis, Polyarteritis nodosa, Polymyalgia rheumatica, Septic aortitis, Stroke, Takayasu arteritis, Transient ischemic attack, Wegener's granulomatosis


References

[1] https://emedicine.medscape.com/article/1612591

[2] https://emedicine.medscape.com/article/332483

[3] Ameer MA, Vaqar S, Khazaeni B. Giant Cell Arteritis (Temporal Arteritis) Updated 2024 May 2: https://www.ncbi.nlm.nih.gov/books/NBK459376/

[4] Garvey TD, Koster MJ, Crowson CS, Warrington KJ. Incidence, survival, and diagnostic trends in GCA across seven decades in a North American population-based cohort. Semin Arthritis Rheum. 2021 Dec;51(6):1193-1199.

[5] Brekke LK, Diamantopoulos AP, Fevang BT, Aβmus J, Esperø E, Gjesdal CG. Incidence of giant cell arteritis in Western Norway 1972-2012: a retrospective cohort study. Arthritis Res Ther. 2017 Dec 15;19(1):278.

Scroll to top